ORLANDO, Fla.--(BUSINESS WIRE)--Researchers at Dana-Farber Cancer Institute in collaboration with MannKind Corporation (Nasdaq:MNKD) generated results confirming that targeting the unfolded protein response (UPR) through the XBP-1 pathway impacts the survival of myeloma cells, suggesting a novel therapeutic strategy in multiple myeloma. The new data generated on a MannKind tool compound were presented as a poster at the 52nd American Society of Hematology (ASH) Annual Meeting.
